FNCH News and Press, Finch Therapeutics Group Inc. From 08/10/21

Finch to transfer FIN-524 program to Takeda for clinical development Finch and Takeda to continue discovery efforts targeting Crohn’s disease SOMERVILLE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finc...

ChrisChrisW/iStock via Getty Images Goldman Sachs has lowered the rating on Seres Therapeutics (MCRB) to sell from neutral, citing the failure of the company to meet the primary endpoint for ulcerative colitis candidate SER-287 in a mid-stage trial. After losing more than half of market ...

Gainers: ImmunoPrecise Antibodies (IPA) +157%.India Globalization Capital (IGC) +74%.NRx Pharmaceuticals (NRXP) +56%.Universe Pharmaceuticals (UPC) +30%.Summit Wireless Technologies (WISA) +28%.Support.com (SPRT) +25%.Agrify Corporation (AGFY) +20%.PainReform (PRFX) +19%.Resources Connec...

Gainers: ImmunoPrecise Antibodies (IPA) +88%, PainReform (PRFX) +48%, NRx Pharmaceuticals (NRXP) +30%, NeuroMetrix (NURO) +27%, Universe Pharmaceuticals (UPC) +18%.Losers: Seres Therapeutics (MCRB) -57%, Jupiter Wellness (JUPW)&...

SOMERVILLE, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class...

The microbiome is an exciting area of medical research that could help treat numerous medical problems such as Crohn's disease, Parkinson's and more. Finch Therapeutics is developing a treatment for C. difficile that was fast tracked by the FDA and is in Phase 3 trials. The compan...

SOMERVILLE, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of ora...

Seth Klarman’s 13F portfolio value increased from $10.84B to $12.56B this quarter. Baupost Group increased Alphabet and Intel while reducing Fox Corp and dropping ViacomCBS. They also built small stakes in several SPACs. The portfolio continues to be heavily concentrated wi...

Finch Therapeutics (FNCH): Q1 GAAP EPS of -$1.00 misses by $0.74.Revenue of $3.55M (+98.3% Y/Y)Press Release For further details see: Finch Therapeutics EPS misses by $0.74

Completed upsized IPO, raising $130.8 million in gross proceeds Topline safety and efficacy data from more than 130 recurrent CDI patients treated with CP101 in PRISM-EXT expected in H2 2021 Strengthened leadership team with the appointment of Susan E. Graf to Board of D...